Peptide Library
Six fully written, fully cited profiles, chosen by US search interest and by how much research exists. Every profile follows the same 10-part template.
Semaglutide
Once-weekly GLP-1 receptor agonist studied in large randomized trials for weight and cardiovascular outcomes.
BPC-157
Synthetic 15-amino-acid peptide. Most results come from animal studies; human data are three small, uncontrolled studies.
GHK-Cu
Copper-binding tripeptide used in skin-care products. Lab and animal work dominates; controlled human data are sparse.
Tirzepatide
The most-searched peptide in the US. An FDA-approved prescription drug, marketed as Mounjaro and Zepbound.
Retatrutide
The most-searched research peptide on Bing. Investigational only, in late-stage trials, and not approved anywhere in the world (ArentFox Schiff).
PT-141 (Bremelanotide)
An FDA-approved drug for one specific indication in premenopausal women, and also widely sold outside that approval.
Why these peptides?
We ranked candidates by average US monthly searches (Peptide Decode, updated 6 Oct 2026) and the size of the research base. That mix pairs approved drugs that have solid human trials with heavily searched research peptides whose evidence is mostly preclinical. A dash means the figure is not reported for that engine.
| Peptide | Google / mo | Bing / mo | Evidence | Status |
|---|---|---|---|---|
| Semaglutide | 368,000 | 32,660 | Approved drug | FDA-approved |
| BPC-157 | – | 19,960 | Mostly animal & lab | Not approved |
| GHK-Cu | 201,000 | 5,250 | Mostly animal & lab | Not approved |
| Tirzepatide | 1,220,000 | 49,780 | Approved drug | FDA-approved |
| Retatrutide | – | 36,430 | Investigational | Investigational |
| PT-141 (Bremelanotide) | 49,500 | 3,240 | Approved drug | FDA-approved |